Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The present disclosure relates in general to methods for the treatment of neurodegenerative disease, such as Huntington's Disease, using compositions comprising cysteamine or cystamine or salts or derivatives thereof.

Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof.

Abstract: Magnetic paper-forming fibers have a particulate magnetic material incorporated within the fibers, as distinct from between the fibers; this can be achieved by loading the lumens of cellulosic fibers with magnetic particles or by generating magnetic particles in situ in a paper-forming fiber which contains ionic groups effective for ion exchange with ferrous ions; the fibers can be employed to produce single layer or multi-layererd magnetic papers for information storage, security paper applications, paper handling, reprographic applications such as magnetographic printing substrate as well as for speciality uses such as electromagnetic shielding, magnetic separation of antibodies based on selective adsorption.